Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.67 |
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.56 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.56 |
| ▸ | RXRA | P19793 | 2/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 3/20 | 0.49 |
| ▸ | F3 | P13726 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450075 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH | |
| SCHEMBL2409345 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH | |
| SCHEMBL2409351 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH | |
| SCHEMBL4915624 | 0.91 | ALDH1A1 (0.83) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH | |
| SCHEMBL4915636 | 0.91 | ALDH1A1 (0.83) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH | |
| SCHEMBL31026998 | 0.89 | ALDH1A1 (0.81) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH | |
| SCHEMBL1424458 | 0.88 | ALDH1A1 (0.78) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH | |
| SCHEMBL1424460 | 0.88 | ALDH1A1 (0.78) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH | |
| SCHEMBL4743544 | 0.88 | ALDH1A1 (0.78) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH | |
| SCHEMBL1424457 | 0.88 | ALDH1A1 (0.78) | ALDH1A1MAPTSMN1; SMN2SLC6A5FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-RE46605-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3210972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Catabasis Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160346397-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9486534-B2 | Niacin conjugated fatty acid mixtures and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2473045-B1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9278136-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9238077-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20130045939-A1 | FATTY ACID MACROLIDE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8304551-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304552-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120264791-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120252850-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120184585-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011116312-A1 | FATTY ACID MACROLIDE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011044141-A1 | FATTY ACID FIBRATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | ALDH1A1 606/4885MAPT 1526/4885SMN1; SMN2 1436/4885 |
| US-20120184585-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | ALDH1A1 606/4885MAPT 1526/4885SMN1; SMN2 1436/4885 |
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | ELOVL5, ELOVL3, ELOVL6 | ALDH1A1 1295/4885MAPT 4554/4885SMN1; SMN2 4299/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | ALDH1A1 3440/4885MAPT 2895/4885SMN1; SMN2 4499/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ALDH1A1 1235/4885MAPT 4397/4885SMN1; SMN2 2004/4885 |
| US-20120264791-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | ALDH1A1 606/4885MAPT 1526/4885SMN1; SMN2 1436/4885 |
| US-20120252850-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | FABP1, NAMPT, ADH1B | ALDH1A1 689/4885MAPT 1848/4885SMN1; SMN2 1674/4885 |
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | ALDH1A1 606/4885MAPT 1526/4885SMN1; SMN2 1436/4885 |
| US-20160346397-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | ALDH1A1 606/4885MAPT 1526/4885SMN1; SMN2 1436/4885 |
| US-20130045939-A1 | FATTY ACID MACROLIDE DERIVATIVES AND THEIR USES | FASN, ELOVL3, FFAR2 | ALDH1A1 3822/4885MAPT 4315/4885SMN1; SMN2 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.